HMOX1 and non-small cell lung carcinoma: NSCLC patients with metastasis and advanced stage disease (III-IV) exhibit a higher and significant expression of HO-1 as compared to early stage and non-metastatic patients and the expression of HO-1 inversely correlates with patient survival [70].